Search Orphan Drug Designations and Approvals
-
| Generic Name: | Liothyronine sodium injection | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Triostat | ||||||||||||||||
| Date Designated: | 07/30/1990 | ||||||||||||||||
| Orphan Designation: | Treatment of myxedema coma/precoma. | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia, Pennsylvania 19101 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | Liothyronine sodium injection |
|---|---|---|
| Trade Name: | Triostat | |
| Marketing Approval Date: | 12/31/1991 | |
| Approved Labeled Indication: | Treatment of myxedema coma/precoma. | |
| Exclusivity End Date: | 12/31/1998 | |
| Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







